The RR is quite good, using the strategy I mentioned, as it eliminates holding into the litmus test that reveals the questionable nature of the company. But then even promising molecules with years of compassionate data and positive phase I/IIa seem to have low COS, so I just avoid "binary" risk altogether.
In some ways I think medical devices are a lot less abstract and able to be treated more like regular businesses but they come with their own can of regulatory and execution worms.
- Forums
- Commodities
- Biotech Analysts $4M pa
The RR is quite good, using the strategy I mentioned, as it...
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
RDN
RAIDEN RESOURCES LIMITED
Dusko Ljubojevic, MD
Dusko Ljubojevic
MD
SPONSORED BY The Market Online